ciglitazone has been researched along with Leukemia, Myeloid in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Mashayekhi, S | 1 |
Yousefi, B | 1 |
Tohidi, E | 1 |
Darband, SG | 1 |
Mirza-Aghazadeh-Attari, M | 1 |
Sadighparvar, S | 1 |
Kaviani, M | 1 |
Shafiei-Irannejad, V | 1 |
Kafil, HS | 1 |
Karimian, A | 1 |
Jadidi-Niaragh, F | 1 |
Majidinia, M | 1 |
1 other study available for ciglitazone and Leukemia, Myeloid
Article | Year |
---|---|
Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Ce | 2019 |